Is it safe to proceed with mitral valve replacement, tricuspid valve annuloplasty, and coronary artery bypass grafting in a diabetic patient with chronic liver disease and hypothyroidism who has elevated blood urea nitrogen/urea but normal creatinine?

Elevated BUN with Normal Creatinine in Cardiac Surgery: Safety Assessment

This patient can proceed to surgery, but requires careful preoperative optimization and heightened perioperative monitoring due to multiple high-risk features. The isolated elevation of BUN with normal creatinine does not represent a contraindication to combined mitral valve replacement, tricuspid annuloplasty, and CABG, but the constellation of comorbidities (diabetes, chronic liver disease, hypothyroidism) significantly increases perioperative risk.

Understanding the BUN-Creatinine Discordance

The pattern of elevated BUN with normal creatinine suggests prerenal azotemia rather than intrinsic renal dysfunction. This is critical because:

• Creatinine remains the primary marker for surgical risk stratification 1, 2, 3
• ACC/AHA guidelines identify preoperative creatinine ≥2 mg/dL as the threshold for significantly increased cardiac surgical risk 1, 2
• Small increases in BUN alone, particularly when creatinine is normal, do not constitute a contraindication to surgery 1, 2

However, the elevated BUN warrants investigation for:

• Volume depletion (most common cause)
• High protein catabolism
• GI bleeding
• Heart failure with poor renal perfusion
• Medication effects (especially if on ACE inhibitors or diuretics)

Critical Risk Factors in This Patient

1. Diabetes Mellitus - Major Concern

Diabetes is identified as an independent risk factor for cardiac morbidity in cardiac surgery 2, 4, 3:

• Insulin-requiring diabetes specifically increases perioperative cardiac complications
• Diabetic patients have higher rates of postoperative heart failure
• Increased risk of wound infections and poor healing
• Insulin-dependent diabetes is also a predictor of bradyarrhythmia requiring pacemaker after mitral valve surgery 5

Preoperative optimization required:

• Achieve HbA1c <7% if time permits (ideally <8% minimum)
• Plan for continuous IV insulin infusion perioperatively (superior to subcutaneous dosing) 2
• Aggressive glucose control (target 140-180 mg/dL) reduces wound infections 2

2. Chronic Liver Disease - Significant Concern

While not extensively addressed in cardiac surgery guidelines, chronic liver disease (CLD) substantially increases surgical risk through:

• Coagulopathy and bleeding risk
• Impaired drug metabolism
• Poor wound healing
• Increased infection risk
• Potential for hepatorenal syndrome perioperatively

Essential preoperative assessment:

• Calculate MELD score to quantify liver dysfunction severity
• Obtain coagulation studies (PT/INR, PTT, platelet count)
• Assess synthetic function (albumin, bilirubin)
• If cirrhotic: evaluate for portal hypertension, varices, ascites
• Consider hepatology consultation for risk stratification

3. Hypothyroidism - Manageable Risk

• Must be euthyroid before elective surgery
• Continue thyroid replacement through surgery
• Verify TSH is in normal range preoperatively

Specific Surgical Considerations

Tricuspid Annuloplasty Adds Risk

The addition of tricuspid valve annuloplasty to mitral valve surgery carries specific implications:

• Increased operative time: Cross-clamp times increase by 5-17 minutes, CPB times by 8-50 minutes 6
• Pacemaker requirement: Tricuspid annuloplasty is an independent risk factor for permanent pacemaker (OR 2.348) 5
• Combined with diabetes: This patient has two independent risk factors for bradyarrhythmia
• Early mortality: Some studies show increased 30-day mortality (14% vs 5%) 7, though meta-analyses suggest no significant increase when properly selected 6
• Heart failure hospitalizations: Higher rates post-discharge (31% vs 17%) 7

However, concomitant tricuspid repair is indicated when performed with mitral surgery if there is 8:

• Tricuspid annular dilation ≥40 mm, OR
• Moderate or greater functional tricuspid regurgitation

Mitral Valve Replacement vs Repair

Guidelines strongly favor repair over replacement when feasible 8, 9, 8, but replacement may be necessary based on valve pathology. The choice affects:

• Pacemaker risk: Replacement carries higher risk than repair (OR 1.905) 5
• Anticoagulation requirements (mechanical valve)
• Long-term durability

Preoperative Optimization Strategy

Immediate Actions:

1. Correct the prerenal azotemia:

   • Optimize volume status
   • Hold diuretics if volume depleted
   • Ensure adequate hydration
   • Recheck BUN/creatinine after correction

2. Calculate actual renal function:

   • Obtain creatinine clearance or eGFR using MDRD equation 1, 3
   • This provides more accurate risk assessment than creatinine alone
   • If eGFR <60 mL/min/1.73m², risk increases substantially

3. Comprehensive metabolic assessment:

   • Liver function tests (AST, ALT, bilirubin, albumin, PT/INR)
   • MELD score calculation
   • TSH level
   • HbA1c
   • Complete blood count

4. Cardiac risk stratification:

   • Calculate STS risk score (Society of Thoracic Surgeons) 10
   • This incorporates multiple comorbidities for mortality prediction
   • Essential for informed consent and surgical planning

Perioperative Management Plan:

Glycemic control:

• Continuous IV insulin infusion targeting 140-180 mg/dL 2
• Avoid hypoglycemia (increases cardiac events)
• Frequent glucose monitoring (hourly initially)

Renal protection:

• Maintain adequate intravascular volume and perfusion pressure
• Avoid nephrotoxic agents
• Monitor urine output closely
• Consider hemodynamic monitoring (arterial line, central line)

Liver considerations:

• Correct coagulopathy preoperatively if present
• Minimize hepatotoxic medications
• Anticipate increased bleeding risk

Thyroid management:

• Continue levothyroxine perioperatively
• Can give IV if NPO prolonged

Risk-Benefit Analysis

Proceed with surgery if:

• BUN normalizes or improves with hydration
• Creatinine remains normal and eGFR >45 mL/min/1.73m²
• Liver function is compensated (MELD <15-20)
• Patient is euthyroid
• Diabetes is reasonably controlled (HbA1c <8.5%)
• Cardiac indications are compelling (symptomatic valve disease, ischemia)

Delay surgery for optimization if:

• Severe volume depletion with ongoing BUN elevation
• Uncontrolled diabetes (HbA1c >9%)
• Decompensated liver disease
• Uncontrolled hypothyroidism

Consider surgery too high risk if:

• MELD score >20-25 (prohibitive liver dysfunction)
• eGFR <30 mL/min/1.73m² (severe renal impairment)
• Multiple organ system failures

Common Pitfalls to Avoid

1. Don't dismiss elevated BUN as "just prerenal" without correcting it and reassessing
2. Don't rely on creatinine alone in diabetic patients—calculate eGFR 1, 3
3. Don't underestimate the combined risk of diabetes + tricuspid annuloplasty for pacemaker requirement 5
4. Don't proceed without hepatology input if significant liver disease suspected
5. Don't forget aggressive perioperative glucose control—it significantly reduces complications 2

Bottom Line

Surgery can proceed safely if prerenal azotemia is corrected and comorbidities are optimized. The normal creatinine is reassuring, but this patient's diabetes, chronic liver disease, and the planned tricuspid annuloplasty create a moderate-to-high risk profile. Success depends on meticulous preoperative optimization, expert surgical technique at a high-volume center, and intensive perioperative management. A multidisciplinary Heart Team discussion including hepatology consultation is essential for optimal risk stratification and surgical planning 10.